31 related articles for article (PubMed ID: 21172105)
1. Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review.
Kith G; Lisker S; Sarkar U; Barr-Walker J; Breyer BN; Palmer NR
Eur Urol Oncol; 2021 Apr; 4(2):192-201. PubMed ID: 31288992
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.
An JY; Sidana A; Choyke PL; Wood BJ; Pinto PA; Türkbey İB
Balkan Med J; 2017 Sep; 34(5):388-396. PubMed ID: 28990929
[TBL] [Abstract][Full Text] [Related]
3. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
4. Five-year nationwide follow-up study of active surveillance for prostate cancer.
Loeb S; Folkvaljon Y; Makarov DV; Bratt O; Bill-Axelson A; Stattin P
Eur Urol; 2015 Feb; 67(2):233-8. PubMed ID: 24993868
[TBL] [Abstract][Full Text] [Related]
5. Regional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan.
Koizumi C; Suetomi T; Matsuoka T; Ikeda A; Kimura T; Onozawa M; Miyazaki J; Kawai K; Takahashi H; Akaza H; Nishiyama H
Prostate Int; 2014 Mar; 2(1):19-25. PubMed ID: 24693530
[TBL] [Abstract][Full Text] [Related]
6. Implementation of PSA-based active surveillance in prostate cancer.
Jalloh M; Cooperberg MR
Biomark Med; 2014; 8(5):747-53. PubMed ID: 25123041
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
8. Interval from prostate biopsy to radical prostatectomy: effect on PSA, Gleason sum, and risk of recurrence.
Shibata A; Mohanasundaram UM; Terris MK
Urology; 2005 Oct; 66(4):808-13. PubMed ID: 16230143
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
10. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
[TBL] [Abstract][Full Text] [Related]
11. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance for prostate cancer in a veteran population.
Lee EK; Baack J; Penn H; Bromfield CT; Duchene DA; Thrasher JB; Holzbeierlein JM
Can J Urol; 2010 Dec; 17(6):5429-35. PubMed ID: 21172105
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance: pitfalls to consider.
Ercole B; Parekh DJ
Arch Esp Urol; 2011 Oct; 64(8):695-702. PubMed ID: 22052752
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]